Fig. 3From: How can a joint European health technology assessment provide an ‘additional benefit’ over the current standard of national assessments?Evolving challenges for development of comparative evidence in oncology medicines (Mean per stakeholder group). The questions that was asked in the questionnaire: ‘A key challenge for future oncology medicines is deriving comparative evidence..’Back to article page